Spectral Diagnostics (EDTXF) 0.3622 $EDTXF
Spectral to Present at the 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) in San Diego
Marketwired - Thu Feb 12, 7:04AM CST
Spectral Medical Inc. ("Spectral" or the "Company"
(TSX: EDT)(OTCQX: EDTXF) a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, today announced that it will present at the upcoming 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) conference in San Diego, California on February 18, 2015 during an interactive luncheon session.
EDT.TO: 0.46 (+0.07)
Spectral on Track for Potential Commercialization in the First Half of 2016
Marketwired - Mon Jan 26, 7:02AM CST
Spectral Medical Inc. ("Spectral" or the "Company" (TSX: EDT)(OTCQX: EDTXF), a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced continuing progress towards commercialization of a medical device that addresses the critical care needs of patients in a $3 billion market.
EDT.TO: 0.46 (+0.07)
Spectral to Present at the 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) in San Diego
Marketwired - Thu Feb 12, 7:04AM CST
Spectral Medical Inc. ("Spectral" or the "Company"
(TSX: EDT)(OTCQX: EDTXF) a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, today announced that it will present at the upcoming 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) conference in San Diego, California on February 18, 2015 during an interactive luncheon session. EDT.TO: 0.46 (+0.07)
Spectral on Track for Potential Commercialization in the First Half of 2016
Marketwired - Mon Jan 26, 7:02AM CST
Spectral Medical Inc. ("Spectral" or the "Company"
(TSX: EDT)(OTCQX: EDTXF), a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced continuing progress towards commercialization of a medical device that addresses the critical care needs of patients in a $3 billion market. EDT.TO: 0.46 (+0.07)
